Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
The prevalence rates in Europe, China, and North America were close to 1.5%, but significant variations exist between different regions and populations
But other indulgent treat manufacturers have seen negligible changes, with PepsiCo CEO Ramon Laguarta telling analysts last month the company hasnt seen a direct impact from GLP-1 medications
Addiction, Alzheimers, rheumatoid arthritis and cardiovascular disease are just some of the areas beyond obesity and diabetes showing potential as GLP-1 targets and igniting research around the globe all due to the underrecognized power of basic science
GLP-1s and Endurance Performance: What Athletes Need to Know Dec 10, 2025 GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) have quickly gained attention for their dramatic effects on weight loss and appetite control
The degree of that rise depends on the individual, their other medications, their diet and their level of physical activity
US$ 27.92
US$ 21.64
US$ 27.72
